Luxury Industry Confronts Structural Shifts Amid Persistent Price Increases

by THEFUTURE.TEAM

November 21, 2025

The global luxury sector is poised for modest growth next year, with forecasted sales increases in the 3% to 5% range following a period of stagnation. However, years of relentless price hikes are now threatening long‑term expansion by alienating both aspirational buyers and even the ultra‑affluent, according to insights from Bain & Company.

Industry Growth And Regional Dynamics

Bain’s analysis indicates that the future uplift will be fueled by steady momentum in the United States, resilient local demand in Europe and Japan, and a gradual recovery of trends in China. This multifaceted growth, however, is shadowed by a troubling trend of pricing strategies that are distancing a broad customer base.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The Price Hike Challenge

Bain warns that the persistent price increases have not only priced out aspirational consumers but have also left high‐end clients feeling betrayed. Federica Levato, a partner at Bain, said, “You cannot target only the top customers. They are starting to feel betrayed by the industry’s escalating prices.” This sentiment comes as luxury brands attempt to rectify past missteps with new creative initiatives—an approach that Levato doubts will suffice if the underlying pricing issue remains unresolved.

The Impact On Customer Loyalty

The luxury customer base shrank from 400 million in 2022 to approximately 340 million in 2025, with forecasts predicting a further decline of 20 to 30 million clients. Even as big spenders now represent around 46-47% of the €358 billion personal luxury goods market, their spending has plateaued, indicating a broader consumer fatigue.

Navigating Excess Inventory

Another significant challenge for industry players is the mounting inventory. Stock-to-revenue ratios have increased by three to four percentage points compared to 2019. Levato suggests that luxury brands may need to leverage outlet channels and off‑price e‑commerce to clear excess product—a strategy complicated by concerns over brand image and strict EU sustainability regulations that prevent the destruction of unsold goods.

Future Forecast Amid Uncertainty

Geopolitical uncertainties, including fluctuating trade policies and economic questions in markets like China, add to the complexity of forecasting the industry’s trajectory. Notably, Kering CEO Luca de Meo has already signaled a need to reassess pricing and product strategies following years of aggressive increases. With luxury shares rallying—evidenced by the Stoxx Luxury 10 index, which recovered 19% from its April lows—the industry is at a critical juncture where rebalancing market appeal and sustainable growth remains paramount.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news